Recommended Dose: For chronic hepatitis B and C: 30–50 μg per injection, administered once daily for the first month, then changed to once every other day for a total treatment course of 6–12 months. For hairy cell leukemia: 30–50 μg once daily via subcutaneous injection for more than 6 consecutive months. For condyloma acuminatum: 10–50 μg injected locally at lesion base once every other day for 3–6 weeks.

Time: Injection can be performed at any fixed time of the day, independent of meal status. Maintain fixed dosing intervals for long-term treatment courses.

Instructions for use: Reconstitute lyophilized powder completely with matched sterile water for injection before use. Administer via subcutaneous or intramuscular injection; perform local lesion basal injection for cutaneous warts. Monitor routine blood cell count, liver function and thyroid function regularly throughout treatment. Discontinue dosing immediately if severe flu-like symptoms or severe myelosuppression occurs. Adjust dose or suspend treatment according to adverse reaction severity.

Interaction: Concurrent immunosuppressants reduce interferon-mediated immune activation and weaken antiviral and anti-tumor efficacy. Combined with antiviral nucleoside analogs produces synergistic viral suppression effect. Concurrent myelosuppressive drugs increase leukopenia and thrombocytopenia risk, requiring close hematological monitoring.

Side effects:

1. Common mild to moderate adverse reactions: influenza-like symptoms including fever, fatigue, myalgia, headache and chills, mild injection site redness and swelling, transient mild leukopenia.

2. Severe rare adverse reactions: severe persistent myelosuppression, severe liver function damage, aggravated autoimmune diseases, severe allergic anaphylaxis, severe cardiac arrhythmia.